• linkedin
  • Increase Font
  • Sharebar

    AUA '17 puts emphasis squarely on 'value'

    New era of value-based care permeates policy, clinical presentations


    Epidemiologic Trends/Practice Patterns, Quality of Life

    Peter C. Albertsen, MDDr. AlbertsenThree-year functional outcomes after commonly used treatments for localized prostate cancer, antimuscarinic use in the elderly, and a financial analysis of scribe use in ambulatory urologic practice are among the top papers in the “General & Epidemiologic Trends & Socieoconomics: Practice Patterns, Quality of Life and Shared Decision Making” portion of the program. That is the assessment of Peter C. Albertsen, MD, chief of urology at the University of Connecticut Health Center, Farmington.

    These are the abstracts Dr. Albertsen says to watch for at this year's meeting:

    PD09-03: Three-year functional outcomes after radiation, surgery or observation for localized prostate cancer in the CEASAR study

    Daniel Barocas


    MP69-01: Antimuscarinic use in the elderly: A poisoned apple?

    Daniel Pucheril


    MP76-01: Sharp decrease in prostate biopsy incidence with wide geographic variation following task force prostate cancer screening recommendations

    Mark Henry


    MP76-02: Urologist practice affiliation and intensity modulated radiation therapy for prostate cancer

    Lindsey Herrel


    MP76-13: Scribes in ambulatory urologic practice: financial analysis and practice management considerations

    Madeline Cancian


    PD09-06: Can a simple count of several common comorbidities accurately predict long-term, other cause mortality in men with prostate cancer?

    Kian Asanad

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available